



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051	BSE Limited, Pheroze Jeejeebhoy Tower, Dalal Street, Mumbai- 400 001
Security Symbol: IOLCP	Security Code : 524164

IOLCP/CGC/2019
Date: 30 May 2019

Sub. Copy of Financial results published in newspapers


Dear Sir,

Pursuant to Regulation 47 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copy of Financial results for the quarter and year ended 31 March 2019 published in Business Standard, Economic Times, Financial Express' and 'Punjabi Jagran' on 30 May 2019.

This is for your information please.

Thanking You,

Yours faithfully,
For IOL Chemicals and Pharmaceuticals Limited


Krishan Singla
Vice President & Company Secretary
Membership No. A5584





IOL Chemicals and Pharmaceuticals Limited

KEY HIGHLIGHTS OF RESULTS



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019 (Rs. in Crore)

Sr. No	Particulars	Quarter ended		Year ended	
		31.03.2019 (Audited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
1	Total income from operations	424.49	290.65	1695.70	1007.29
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	142.52	12.73	336.15	31.30
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	142.52	12.73	336.15	31.30
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	101.65	11.49	236.70	27.70
5	Total Comprehensive income for the period (comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax))	100.25	10.84	235.30	27.05
6	Equity share capital	56.89	56.21	56.89	56.21
7	Other equity (Reserves excluding revaluation reserve)			417.45	159.53
8	Earning per share (of Rs.10/- each) (for continuing and discontinued operations) (not annualised except for year ended 31.03.2019 and 31.03.2018)				
	Basic	18.08	2.05	42.11	4.93
	Diluted	18.08	2.05	42.11	4.93
	Cash	21.39	3.18	52.77	9.75

Notes:

- The above is an extract of the detailed format of quarterly/ year ended financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly / year ended financial results is available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com
- The Company has allotted 25,00,000 warrants at Rs.205/- per warrants to a promoter on 30 March 2019 with an option to subscribe to an equity share of face value of Rs. 10/- at a price of Rs.205/- per equity share including premium of Rs.195/-per share and has allotted 6,82,000 equity shares to the promoter on exercise of the option attached with warrants. The paid up capital of the company has increased to 5,68,87,502 equity shares of Rs. 10/- each on allotment of these shares.
- The company has enhanced existing manufacturing facilities of Ibuprofen from 10000 MT per annum to 12000 MT per annum and Iso Butyl Benzene from 9000 MT per annum to 12000 MT per annum in May 2019 at aggregate capex of Rs. 12.10 crore which is met from internal accruals.
- The company has pre-paid Rs.47.62 crore to the banks in addition to regular repayments, to reduce the debt.
- Excise duty realized is included in revenue from operations of the period ended upto 30 June 2017 and revenue from operations for the subsequent periods are net of Goods and Services Taxes (GST). Accordingly the figures of the revenue from operations for the previous year ended 31 March 2018 are not comparable with figures of the year ended 31 March 2019.
- Effective 1 April 2018, the company has adopted Ind AS 115 revenue from contracts with customers and its application did not have any material impact on the financial results of the company.
- The previous financial period figures have been regrouped/rearranged/restated wherever considered necessary.

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited
Sd/-

Vijay Garg
Joint Managing Director
DIN: 08510248

Place: Barnala
Date: 29 May 2019

CIN: L24116PB1986PLC007030, Regd. Office: Indent Complex, Raitot Road, Barnala-148101, Punjab
Ph: +91-1679-244701-07, Fax: +91-1679-244708, E-mail: contact@iolcp.com, www.iolcp.com

IOL Chemicals and Pharmaceuticals Limited

KEY HIGHLIGHTS OF RESULTS



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019 (Rs. in Crore)

Sr. No.	Particulars	Quarter ended		Year ended	
		31.03.2019	31.03.2018	31.03.2019	31.03.2018
		(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from operations	424.49	290.65	1695.70	1007.29
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	142.52	12.73	336.15	31.30
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	142.52	12.73	336.15	31.30
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	101.65	11.49	236.70	27.70
5	Total Comprehensive Income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	100.25	10.84	235.30	27.05
6	Equity share capital	56.89	56.21	56.89	56.21
7	Other equity (Reserves excluding revaluation reserve)			417.45	159.53
8	Earning per share (of Rs.10/- each) (for continuing and discontinued operations) (not annualised except for year ended 31.03.2019 and 31.03.2018)				
	Basic	18.08	2.05	42.11	4.93
	Diluted	18.08	2.05	42.11	4.93
	Cash	21.39	3.18	52.77	9.75

Notes:

- The above is an extract of the detailed format of quarterly/ year ended financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly / year ended financial results is available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com
- The Company has allotted 25,00,000 warrants at Rs.205/- per warrants to a promoter on 30 March 2019 with an option to subscribe to an equity share of face value of Rs.10/- at a price of Rs.205/- per equity share including premium of Rs.195/- per share and has allotted 8,82,000 equity shares to the promoter on exercise of the option attached with warrants. The paid up capital of the company has increased to 5,68,87,502 equity shares of Rs.10/- each on allotment of these shares.
- The company has enhanced existing manufacturing facilities of Ibuprofen from 10000 MT per annum to 12000 MT per annum and Iso Butyl Benzene from 8000 MT per annum to 12000 MT per annum in May 2019 at aggregate capex of Rs.12.10 crore which is met from internal accruals.
- The company has pre-paid Rs.47.62 crore to the banks in addition to regular repayments, to reduce the debt.
- Excise duty realized is included in revenue from operations of the period ended upto 30 June 2017 and revenue from operations for the subsequent periods are net of Goods and Services Taxes (GST). Accordingly the figures of the revenue from operations for the previous year ended 31 March 2018 are not comparable with figures of the year ended 31 March 2019.
- Effective 1 April 2018, the company has adopted Ind AS 115 revenue from contracts with customers and its application did not have any material impact on the financial results of the company
- The previous financial period figures have been regrouped/rearranged/restated wherever considered necessary.

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited

Sd/-
Vijay Garg
Joint Managing Director
DIN: 06510248

Place: Barnala
Date: 29 May 2019

CIN: L29116PB1986PLC007030. Regd. Office: Trident Complex, Rukh Road, Barnala-148101, Punjab
Ph: +91-1879-244705, Fax: +91-1879-244705, E-mail: contact@iolcp.com, www.iolcp.com

THURSDAY, MAY 30, 2019

36

IOL Chemicals and Pharmaceuticals Limited

KEY HIGHLIGHTS OF RESULTS



EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019 (Rs. in Crore)

Sr. No.	Particulars	Quarter ended		Year ended	
		31.03.2019 (Audited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
1	Total Income from operations	424.49	290.65	1695.70	1007.29
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	142.52	12.73	336.15	31.30
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	142.52	12.73	336.15	31.30
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	101.65	11.49	236.70	27.70
5	Total Comprehensive Income for the period (comprising profit/loss) for the period (after tax) and other comprehensive income (after tax)	100.25	10.84	235.30	27.05
6	Equity share capital	56.89	56.21	56.89	56.21
7	Other equity (Reserves excluding revaluation reserve)			417.45	159.53
8	Earning per share (of Rs.10/- each) (for continuing and discontinued operations) (not annualised except for year ended 31.03.2019 and 31.03.2018)				
	Basic	18.08	2.05	42.11	4.93
	Diluted	18.08	2.05	42.11	4.93
	Cash	21.39	3.18	52.77	9.75

Notes:

- The above is an extract of the detailed format of quarterly/ year ended financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly / year ended financial results is available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com
- The Company has allotted 25,00,000 warrants at Rs.205/- per warrant to a promoter on 30 March 2019 with an option to subscribe to an equity share of face value of Rs.10/- at a price of Rs.205/- per equity share including premium of Rs.195/- per share and has allotted 6,82,000 equity shares to the promoter on exercise of the option attached with warrants. The paid up capital of the company has increased to 5,68,87,502 equity shares of Rs. 10/- each on allotment of these shares.
- The company has enhanced existing manufacturing facilities of Ibuprofen from 10000 MT per annum to 12000 MT per annum and Iso Butyl Benzene from 9000 MT per annum to 12000 MT per annum in May 2018 at aggregate capex of Rs.12.10 crore which is met from internal accruals.
- The company has pre-paid Rs.47.62 crore to the banks in addition to regular repayments, to reduce the debt.
- Excise duty realized is included in revenue from operations of the period ended upto 30 June 2017 and revenue from operations for the subsequent periods are net of Goods and Services Tax (GST). Accordingly the figures of the revenue from operations for the previous year ended 31 March 2018 are not comparable with figures of the year ended 31 March 2019.
- Effective 1 April 2018, the company has adopted Ind AS 116 revenue from contracts with customers and its application did not have any material impact on the financial results of the company.
- The previous financial period figures have been reworked/retained/omitted wherever considered necessary.

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited
Sd/-
Vijay Garg
Joint Managing Director
DIN: 06510248

Place: Bamals
Date: 29 May 2019

101, Floor, 5/16, Sector-4, Aligarh, Lucknow-24. Ph: 9522-482512

NEW DELHI MUNICIPAL CORPORATION
Tender ID No. - 2019_NDMC_173016
Name of work: Strengthening of drainage system at Bangla Sahib Road.
Sub Head : Providing and laying NP2 class 600 mm dia RC
Estimated Cost : ₹ 10,99,197/-
Date of release of tender : 28.05.2019
Last date/time for receipt of tenders : 11.06.2019 upto 4.
Further details can be seen at <http://govtprocurement.delhi.gov.in>
Note: To participate in a tender in NDMC, registration with the Government of NCT of Delhi is mandatory.

PROGRESSIVE URBAN COOPERATIVE BANK LTD.
1st Floor, 5/16, Sector-4, Aligarh, Lucknow-24. Ph: 9522-482512

REQUIRED
The Bank is looking for a CEO/ Secretary with strategic vision, skilled management & communication skills. The Candidate must be computer savvy & must have working knowledge in Banking Sector. Person should be below the age of 50 years. Recruitment will be salary based as per the terms & conditions of the Bank. Candidates may apply along with a recent photograph by post of email at puckk_k@yahoo.com listed by 3rd of June.

Form no INC-26
[Pursuant to rule 30 of the Companies (Incorporation) Rules, 2014]
Advertisement to be published in the newspaper for change of registered office of the company from one state to another before the Central Government
The Regional Director, Northern Region, New Delhi, Delhi
in the matter of sub-section (4) of section 13 Companies Act, 2013 and clause (a) of sub-rule (5) of rule 30 of the Companies (Incorporation) Rules, 2014
AND
in the matter of M/s DND Exam Private Limited having its registered office at 225, 2nd Floor, Sant Nagar, East of Kailash, Delhi-110065,
—Petitioner.

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under section 13 of the Companies Act, 2013 seeking confirmation of alteration of the Memorandum of Association of the Company in terms of the special resolution passed at the Extra-Ordinary General meeting held on 15th May, 2019 to enable the Company to change its Registered office from "The National Capital Territory (NCT) of Delhi" to "The State of Uttar Pradesh".

Any person whose interest is likely to be affected by the proposed change of the registered office of the Company may deliver either on the MCA 21 portal (www.mca.gov.in) by filing investor complaint form or cause to be delivered or send by registered post of his/her objections supported by an affidavit stating the nature of his/her interest and grounds of opposition to the Regional Director, Northern Region, New Delhi, Delhi at the address B-2 Wing, 2nd Floor, Paryavaran Bhawan, CGO Complex, New Delhi - 110003, within Fourteen days from the date of publication of this notice with a copy of the applicant Company at its registered office at the address mentioned below.

Registered office: 225, 2nd Floor, Sant Nagar, East of Kailash, Delhi-110065
For and on behalf of M/s DND EXAM PRIVATE LIMITED Sd/- (Anshu Singh) Director
Date: 15/05/2019
Place: New Delhi
DIN: 01168120

Sr. No.	Particulars	31.03.2019	31.03.2018
1	Total Income from operations	1695.70	1007.29
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	336.15	31.30
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	336.15	31.30
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	236.70	27.70
5	Total Comprehensive Income for the period (comprising profit/loss) for the period (after tax) and other comprehensive income (after tax)	235.30	27.05
6	Equity Share Capital	56.89	56.21
7	Reserves (excluding shown in the Audit previous year)	417.45	159.53
8	Earnings per share: continuing operations		
	1. Basic	42.11	4.93
	2. Diluted	42.11	4.93

केनरा
Whereas, The undersigned has taken a Demand Notice dated 12/05/2019 at Friends Colony, New Delhi for the amount mentioned in the Demand Notice dated 12/05/2019. The Borrower above mentioned has taken a Demand Notice dated 12/05/2019. The Borrower/ Guarantor has taken any dealings with the undersigned at Friends Colony, New Delhi for the amount mentioned in the Demand Notice dated 12/05/2019. Three Thousand Eight

